This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bayer Drug Hailed as Prostate Cancer Game Changer

BOSTON ( TheStreet) -- An experimental drug from Germany's Bayer and the Norwegian biotech firm Algeta extended the lives of advanced prostate cancer patients by zapping tumors that invade bone with small doses of radiation, according to data from a late-stage study presented this weekend.

The Bayer/Algeta drug known as Alpharadin was hailed as a major advance in prostate cancer treatment by experts at a European cancer research meeting in Sweden because the drug is the first to improve bone symptoms and prolong survival.

Bayer plans to seek U.S. approval of Alpharadin in the middle of 2012. The emergence of Alpharadin complicates and may even block efforts by Amgen (AMGN - Get Report) and Exelixis (EXEL) to advance their respective prostate cancer drugs.

Amgen's Xgeva is approved as a treatment for bone-related complications of cancer and the company is now seeking FDA approval to expand the drug's use to include a claim that it can delay the spread of prostate cancer to bone. Xgeva, however, does not help prostate cancer patients live longer.

Exelixis' experimental cancer drug cabozantinib, like Alpharadin, specifically targets prostate cancer that spreads to bone, but has not yet demonstrated that it can prolong survival. Exelixis is seeking FDA permission to conduct a registration study of cabozantinib that would rely on pain reduction and bone scan resolution as primary endpoints and the basis for the drug's approval.

FDA may balk at Exelixis' request without data showing that cabozantinib also helps patients live longer, especially now that Alpharadin has set a new standard for treatment.

"Alpharadin raises the bar for Exelixis. They have to produce overall survival data now," said Sally Church, a cancer drug consultant with Icarus Consultants who also co-writes the widely followed Biotech Strategy Blog.

"Alpharadin's overall survival data doesn't change our strategy," said Exelixis spokesman Charles Butler, in an email response to questions about the Bayer/Algeta drug.

Bayer/Algeta's Alpharadin, also known as Radium-233 is a new type of drug that delivers small, short-ranged doses of alpha radiation directly to prostate cancer that has spread to bones. The so-called "alpha pharmaceutical" specifically targets bone lesions with its radiation because it contains radium, which like calcium, sticks to bones. As a result, Alpharadin doesn't negatively affect surrounding, healthy tissue.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMGN $151.99 0.26%
DNDN $0.06 -6.02%
EXEL $3.64 2.80%
JNJ $97.32 -0.37%
MDVN $112.33 2.00%

Markets

DOW 17,614.37 +18.02 0.10%
S&P 500 2,060.03 +2.39 0.12%
NASDAQ 4,974.8270 +16.3590 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs